L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model

Pharmacology Biochemistry and Behavior

Volumn 127, Issue , 2014, Pages 62-69

  Ando, Kiyoshi ^a   Inoue, Takashi ^a   Itoh, Toshio ^a  

^a CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

Author keywords

Behavioral sensitization; Common marmoset; Dyskinesia; l DOPA; Monkey; Motor activity; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA PLUS LEVODOPA; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANTIPARKINSON AGENTS; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALLITHRIX; CHOREA; CONTROLLED STUDY; DOSE RESPONSE; DYSKINESIA; EXPERIMENTAL MODEL; MALE; MOTOR ACTIVITY; NONHUMAN; PARKINSON DISEASE; PREDICTIVE VALUE; SENSITIZATION; ANIMALS; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; PARKINSONIAN DISORDERS; PHYSIOLOGY; PHYSIOPATHOLOGY; PSYCHOLOGY; RANDOM ALLOCATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; CALLITHRIX; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MALE; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; RANDOM ALLOCATION;

EID: 84909943650     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2014.10.009     Document Type: Article

References (73)

1. U. Adamiak, M. Kaldonska, G. Klodowska-Duda, E. Wyska, K. Safranow, and M. Bialecka Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease Clin Neuropharmacol 33 2010 135 141
2. J.E. Ahlskog, and M.D. Muenter Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov Disord 16 2001 448 458
3. L. Alvarez, R. Macias, N. Pavon, G. Lopez, M.C. Rodriguez-Oroz, and R. Rodriguez Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36 months J Neurol Neurosurg Psychiatry 80 2009 979 985
4. K. Ando, J. Maeda, M. Inaji, T. Okauchi, S. Obayashi, and M. Higuchi Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets Psychopharmacology 195 2008 509 516
5. K. Ando, S. Obayashi, Y. Nagai, A. Oh-Nishi, T. Minamimoto, and M. Higuchi PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease PLoS ONE 7 2012 e46371
6. M. Balls, A.M. Goldberg, J.H. Fentem, C.L. Broadhead, R.L. Burch, and M.F. Festing The three Rs: the way forward: the report and recommendations of ECVAM Workshop 11 Altern Lab Anim 23 1995 838 866
7. P.J. Bedard, T. Di Paolo, P. Falardeau, and R. Boucher Chronic treatment with l-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding Brain Res 379 1986 294 299
8. C. Beurrier, and R.C. Malenka Enhanced inhibition of synaptic transmission by dopamine in the nucleus accumbens during behavioral sensitization to cocaine J Neurosci 22 2002 5817 5822
9. P.J. Blanchet, P. Allard, L. Gregoire, F. Tardif, and P.J. Bedard Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients Can J Neurol Sci J Can Sci Neurol 23 1996 189 193
10. P. Calabresi, M. Di Filippo, V. Ghiglieri, N. Tambasco, and B. Picconi Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap Lancet Neurol 9 2010 1106 1117
11. F. Calon, M. Goulet, P.J. Blanchet, J.C. Martel, M.F. Piercey, and P.J. Bedard Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex Brain Res 680 1995 43 52
12. F. Calon, R. Grondin, M. Morissette, M. Goulet, P.J. Blanchet, and T. Di Paolo Molecular basis of levodopa-induced dyskinesias Ann Neurol 47 2000 S70 S78
13. A.R. Carta, L. Frau, A. Pinna, S. Pontis, N. Simola, and N. Schintu Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat Synapse 62 2008 524 533
14. M. Contin, and P. Martinelli Pharmacokinetics of levodopa J Neurol 257 2010 S253 S261
15. D. Conversi, C. Orsini, V. Colelli, F. Cruciani, and S. Cabib Association between striatal accumulation of FosB/DeltaFosB and long-term psychomotor sensitization to amphetamine in mice depends on the genetic background Behav Brain Res 217 2011 155 164
16. G.C. Cotzias, P.S. Papavasiliou, and R. Gellene Modification of Parkinsonism - chronic treatment with l-DOPA N Engl J Med 280 1969 337 345
17. S.B. Dunnett, and A.E. Rosser Clinical translation of cell transplantation in the brain Curr Opin Organ Transplant 16 2011 632 639
18. G. Ellrichmann, H. Russ, and T. Muller Dyskinesia in Parkinson's disease - major clinical features, aetiology, therapy Fortschr Neurol Psychiatr 75 2007 387 396
19. A. Eslamboli Marmoset monkey models of Parkinson's disease: which model, when and why? Brain Res Bull 68 2005 140 149
20. C. Fehling Treatment of Parkinson's syndrome with l-DOPA. A double blind study Acta Neurol Scand 42 1966 367 372
21. S.H. Fox, and J.M. Brotchie The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future Prog Brain Res 184 2010 133 157
22. S.H. Fox, B. Henry, M. Hill, A. Crossman, and J. Brotchie Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease Mov Disord 17 2002 1180 1187
23. S.H. Fox, R. Katzenschlager, S.Y. Lim, B. Ravina, K. Seppi, and M. Coelho The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease Mov Disord 26 Suppl. 3 2011 S2 S41
24. K. Fuxe, D. Marcellino, S. Genedani, and L. Agnati Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease Mov Disord 22 2007 1990 2017
25. F. Gasparini, T. Di Paolo, and B. Gomez-Mancilla Metabotropic glutamate receptors for Parkinson's disease therapy Park Dis 2013 2013 196028
26. M. Hirabayashi, S. Okada, and S. Tadokoro Comparison of sensitization to ambulation-increasing effects of cocaine and methamphetamine after repeated administration in mice J Pharm Pharmacol 43 1991 827 830
27. P. Huot, T.H. Johnston, J.B. Koprich, S.H. Fox, and J.M. Brotchie The pharmacology of l-DOPA-induced dyskinesia in Parkinson's disease Pharmacol Rev 65 2013 171 222
28. M.J. Hurley, M.J. Jackson, L.A. Smith, S. Rose, and P. Jenner Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets Eur J NeuroSci 21 2005 3240 3250
29. M.J. Jackson, G. Al-Barghouthy, R.K. Pearce, L. Smith, J.J. Hagan, and P. Jenner Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets Pharmacol Biochem Behav 79 2004 391 400
30. P. Jenner Molecular mechanisms of l-DOPA-induced dyskinesia Nat Rev Neurosci 9 2008 665 677
31. P. Jenner From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease Parkinsonism Relat Disord 15 Suppl. 4 2009 S18 S23
32. C.D. Jones, J.A. Bartee, M.L. Leite-Browning, and M.A. Blackshear Methamphetamine-induced locomotor activity and behavioral sensitization: are dopamine d3 receptors involved? Cell Mol Biol 53 2007 15 22
33. K. Kalinderi, L. Fidani, Z. Katsarou, and S. Bostantjopoulou Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease Int J Clin Pract 65 2011 1289 1294
34. P.W. Kalivas, and P. Duffy Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals J Neurosci 13 1993 266 275
35. M.A. Kelly, M.J. Low, M. Rubinstein, and T.J. Phillips Role of dopamine D1-like receptors in methamphetamine locomotor responses of D2 receptor knockout mice Genes Brain Behav 7 2008 568 577
36. C. Kobylecki, M.A. Cenci, A.R. Crossman, and P. Ravenscroft Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease J Neurochem 114 2010 499 511
37. C. Konradi, R.L. Cole, S. Heckers, and S.E. Hyman Amphetamine regulates gene expression in rat striatum via transcription factor CREB J Neurosci 14 1994 5623 5634
38. V. Kostic, S. Przedborski, E. Flaster, and N. Sternic Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease Neurology 41 1991 202 205
39. M. Kuoppamaki, G. Al-Barghouthy, M.J. Jackson, L.A. Smith, N. Quinn, and P. Jenner l-DOPA dose and the duration and severity of dyskinesia in primed MPTP-treated primates J Neural Transm 114 2007 1147 1153
40. J.W. Langston, E.B. Langston, and I. Irwin MPTP-induced parkinsonism in human and non-human primates - clinical and experimental aspects Acta Neurol Scand Suppl 100 1984 49 54
41. R.P. Lesser, S. Fahn, S.R. Snider, L.J. Cote, W.P. Isgreen, and R.E. Barrett Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy Neurology 29 1979 1253 1260
42. A.J. Loonen, and S.A. Ivanova New insights into the mechanism of drug-induced dyskinesia CNS Spectr 18 2013 15 20
43. I.A. Mendez, M.T. Williams, A. Bhavsar, A.P. Lu, J.L. Bizon, and B. Setlow Long-lasting sensitization of reward-directed behavior by amphetamine Behav Brain Res 201 2009 74 79
44. S. Miocinovic, S. Somayajula, S. Chitnis, and J.L. Vitek History, applications, and mechanisms of deep brain stimulation JAMA Neurol 70 2013 163 171
45. Y. Misu, and Y. Goshima Is l-DOPA an endogenous neurotransmitter? Trends Pharmacol Sci 14 1993 119 123
46. R.J. Mones, T.S. Elizan, and G.J. Siegel Analysis of l-DOPA induced dyskinesias in 51 patients with Parkinsonism J Neurol Neurosurg Psychiatry 34 1971 668 673
47. T. Muller Drug therapy in patients with Parkinson's disease Transl Neurodegener 1 2012 10
48. T. Muller Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications Clin Neuropharmacol 36 2013 84 91
49. J.E. Nash, S.H. Fox, B. Henry, M.P. Hill, D. Peggs, and S. McGuire Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease Exp Neurol 165 2000 136 142
50. S. Navailles, and P. De Deurwaerdere Imbalanced dopaminergic transmission mediated by serotonergic neurons in l-DOPA-induced dyskinesia Park Dis 2012 2012 323686
51. K. Nishimura, and J. Takahashi Therapeutic application of stem cell technology toward the treatment of Parkinson's disease Biol Pharm Bull 36 2013 171 175
52. R.E. Nordquist, H. Savignac, M. Pauly-Evers, G. Walker, F. Knoflach, and E. Borroni Characterization of behavioral response to amphetamine, tyrosine hydroxylase levels, and dopamine receptor levels in neurokinin 3 receptor knockout mice Behav Pharmacol 19 2008 518 529
53. J.A. Obeso, F. Grandas, J. Vaamonde, M.R. Luquin, J. Artieda, and G. Lera Motor complications associated with chronic levodopa therapy in Parkinson's disease Neurology 39 1989 11 19
54. C.W. Olanow, L.L. Gauger, and J.M. Cedarbaum Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease Ann Neurol 29 1991 556 559
55. W. Olanow, A.H. Schapira, and O. Rascol Continuous dopamine-receptor stimulation in early Parkinson's disease Trends Neurosci 23 2000 S117 S126
56. R.K. Pearce, M. Jackson, L. Smith, P. Jenner, and C.D. Marsden Chronic l-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus) Mov Disord 10 1995 731 740
57. R.K. Pearce, M. Jackson, D.R. Britton, K. Shiosaki, P. Jenner, and C.D. Marsden Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated l-DOPA-primed common marmosets Psychopharmacology 142 1999 51 60
58. R.K. Pearce, M. Heikkila, I.B. Linden, and P. Jenner l-DOPA induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations Psychopharmacology 156 2001 402 409
59. G.M. Petzinger, M. Quik, E. Ivashina, M.W. Jakowec, M. Jakubiak, and D. Di Monte Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate Mov Disord 16 2001 202 207
60. L.F. Potts, H. Wu, A. Singh, I. Marcilla, M.R. Luquin, and S.M. Papa Modeling Parkinson's disease in monkeys for translational studies, a critical analysis Exp Neurol 2013
61. T.E. Robinson, and K.C. Berridge The neural basis of drug craving: an incentive-sensitization theory of addiction Brain Res Brain Res Rev 18 1993 247 291
62. S. Rose, M.J. Jackson, L.A. Smith, K. Stockwell, L. Johnson, and P. Carminati The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of l-DOPA in MPTP treated common marmosets Eur J Pharmacol 546 2006 82 87
63. P. Samadi, M. Morissette, F. Calon, A. Hadj Tahar, M. Dridi, and N. Belanger Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of l-DOPA-induced dyskinesias in MPTP parkinsonian monkeys Synapse 62 2008 101 109
64. L. Shuster, G.W. Webster, and G. Yu Increased running response to morphine in morphine-pretreated mice J Pharmacol Exp Ther 192 1975 64 67
65. L.A. Smith, M.J. Jackson, M.J. Hansard, E. Maratos, and P. Jenner Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure Mov Disord 18 2003 487 495
66. F. Sprenger, and W. Poewe Management of motor and non-motor symptoms in Parkinson's disease CNS Drugs 27 2013 259 272
67. L.C. Tan, P.H. Protell, J.W. Langston, and D.M. Togasaki The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys Mov Disord 17 2002 902 909
68. J.R. Taylor, and J.D. Jentsch Repeated intermittent administration of psychomotor stimulant drugs alters the acquisition of Pavlovian approach behavior in rats: differential effects of cocaine, d-amphetamine and 3,4-methylenedioxymethamphetamine ("ecstasy") Biol Psychiatry 50 2001 137 143
69. D. Terzic, and A. Abosch Update on deep brain stimulation for Parkinson's disease J Neurosurg Sci 56 2012 267 277
70. L.J. Treciokas, R.D. Ansel, and C.H. Markham One to two year treatment of Parkinson's disease with levodopa Calif Med 114 1971 7 14
71. N.P. Visanji, S.H. Fox, T. Johnston, G. Reyes, M.J. Millan, and J.M. Brotchie Dopamine D3 receptor stimulation underlies the development of l-DOPA-induced dyskinesia in animal models of Parkinson's disease Neurobiol Dis 35 2009 184 192
72. R.A. Wise, and K. Leeb Psychomotor-stimulant sensitization: a unitary phenomenon? Behav Pharmacol 4 1993 339 349
73. M. Zappia, R.L. Oliveri, R. Montesanti, M. Rizzo, D. Bosco, and M. Plastino Loss of long-duration response to levodopa over time in PD: implications for wearing-off Neurology 52 1999 763 767